Compare Nuwellis Inc (NUWE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Nuwellis Inc trades at $2.84 (market cap $1.09M), while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 111880.7× Nuwellis Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| NUWE | VRTX | |
|---|---|---|
Market Cap | $1.09M | $121.95B |
Sector | Technology | Health |
52-Week High | $527.46 | $529.59 |
52-Week Low | $2.80 | $366.54 |
Enterprise Value | -$722.58K | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $3.00, up 5.26% today, following a 35:1 reverse stock split effective June 26, 2026. The company shows a low P/E of 0.06 and P/S of 0.01, but fundamentals are weak with a -217.22% net income margin and negative ROE. Recent news highlights patent awards and pediatric market expansion, yet cash flow remains negative. Analyst coverage is limited with a split buy/hold consensus.
Outlook is speculative; growth depends on successful commercialization of Aquadex therapy and cost management. Key risks include persistent losses, high cash burn, and competitive pressures. Investors should weigh low valuation against execution risks in the medical technology sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
